Pilot of Mailing Buprenorphine

NCT07421102 | Recruiting Early Phase 1 DMC

• 2 other identifiers: Pro00146867K12DA031794
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 2

Brief Summary

This pilot study evaluates the feasibility, acceptability, and preliminary effectiveness of mailing buprenorphine to individuals with opioid use disorder (OUD) following medical hospitalization. The intervention aims to improve retention in treatment by overcoming barriers such as transportation and pharmacy access.

Conditions

Opioid Use Disorder

Keywords

mailing buprenorphine; transitions of care; opioid use disorder; barriers to buprenorphine

Outcome Measures

Primary Outcomes (3)

• Feasibility (successful receipt)

  Successful delivery and receipt of medication defined by self-report and phone/text/video confirmation to receive code

  From enrollment to the end of the study at 6 months

• Successful receipt

  Feasibility is defined by the successful receipt of the buprenorphine prescriptions in the mail by the intended participants. Successful receipt defined by self-report and phone/text/video confirmation from participant. Delivery failure is defined as delay in receipt of medication by \>48 hours by the mail delivery service.

  From enrollment to the end of study at 6 months.

• Retention in treatment

  Preliminary effectiveness of mailing buprenorphine will be measured by retention in treatment. This is defined by the proportion of participants retained in buprenorphine treatment at 1,3, and 6 months after discharge.

  time of study enrollment to end of study at 6 months

Study Arms (1)

Mailed Medications

OTHER

There is no comparison arm. This pilot study evaluates the feasibility of mailing medications to patients.

Other: strategy of mailing buprenorphine

Interventions

strategy of mailing buprenorphine OTHER

This study examines the feasibility and preliminary effectiveness of mailing buprenorphine to overcome barriers such as transportation to obtaining buprenorphine from a pharmacy.

Mailed Medications

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18
• English-speaking
• Diagnosed with OUD and initiated on buprenorphine during hospitalization
• Discharging to a South Carolina address with a stable mailbox
• Access to phone or computer

You may not qualify if:

• Active psychosis or suicidal ideation
• Severe medical or neurocognitive impairment
• Pending incarceration

Sponsors & Collaborators

• Medical University of South Carolina: lead
• National Institute on Drug Abuse (NIDA): collaborator

Study Sites (2)

Medical University of South Carolina

Charleston, South Carolina, 29425, United States

NOT YET RECRUITING

Medical University of South Carolina

Charleston, South Carolina, 29425, United States

RECRUITING

MeSH Terms

Conditions

Opioid-Related Disorders

Condition Hierarchy (Ancestors)

Narcotic-Related Disorders; Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders

Study Officials

• Allison Smith, MD

  Medical University of South Carolina

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor-Faculty

Model Details: This is a pilot study designed to study the strategy of mailing buprenorphine and examine feasibility and preliminary effects of the intervention.

Study Record Dates

• First Submitted: February 12, 2026
• First Posted: February 19, 2026
• Study Start: April 1, 2026
• Primary Completion (Estimated): January 1, 2027
• Study Completion (Estimated): March 1, 2027
• Last Updated: April 13, 2026

Record last verified: 2026-04

Locations

US (2)